SUMMARY
This year’s ASCO was an exceptionally good year for thoracic oncology, as more than 300 abstracts on this subject, both under oral and poster form, were discussed in this meeting. Many advances were presented and extensively discussed, of which some are clearly practice changing. In this article I will try to mention the most significant one’s and briefly put them into context. Priority is clearly given to practice changing studies and will be discussed more in detail.
(Belg J Med Oncol 2024;18(5):195–200)
